Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis M Staudt

Showing results (191-200 of 286) with videos related to

Pageof 29
Sort By:
Cancer Cell|April 13, 2016
Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell LymphomaYibin Yang, Priscilla Kelly, Arthur L Shaffer, et al.
Bioorganic & Medicinal Chemistry Letters|November 21, 2007
Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput screens of NFkappaB activationYuli Xie, ShiXian Deng, Craig J Thomas, et al.
Science (New York, N.Y.)|March 8, 2008
Oncogenic CARD11 mutations in human diffuse large B cell lymphomaGeorg Lenz, R Eric Davis, Vu N Ngo, et al.
International Journal of Molecular Epidemiology and Genetics|September 15, 2011
Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab eraLindsay M Morton, James R Cerhan, Patricia Hartge, et al.
Haematologica|August 14, 2008
Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphomaItziar Salaverria, Andreas Zettl, Silvia Beà, et al.
Blood|August 14, 2015
IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphomaChao Wang, Timothy W McKeithan, Qiang Gong, et al.
Blood|October 22, 2005
Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletionsLisa M Rimsza, Robin A Roberts, Elias Campo, et al.
Blood|August 23, 2021
Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behaviorGiorgia Chiodin, Joel D Allen, Dean J Bryant, et al.
Haematologica|November 3, 2009
SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtypeAna Mozos, Cristina Royo, Elena Hartmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2011
BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximabJaveed Iqbal, Paul N Meyer, Lynette M Smith, et al.
Pageof 29

Showing results (191-200 of 286) with videos related to

Sort By:
Pageof 29
Cancer Cell|April 13, 2016
Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell LymphomaYibin Yang, Priscilla Kelly, Arthur L Shaffer, et al.
Bioorganic & Medicinal Chemistry Letters|November 21, 2007
Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput screens of NFkappaB activationYuli Xie, ShiXian Deng, Craig J Thomas, et al.
Science (New York, N.Y.)|March 8, 2008
Oncogenic CARD11 mutations in human diffuse large B cell lymphomaGeorg Lenz, R Eric Davis, Vu N Ngo, et al.
International Journal of Molecular Epidemiology and Genetics|September 15, 2011
Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab eraLindsay M Morton, James R Cerhan, Patricia Hartge, et al.
Haematologica|August 14, 2008
Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphomaItziar Salaverria, Andreas Zettl, Silvia Beà, et al.
Blood|August 14, 2015
IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphomaChao Wang, Timothy W McKeithan, Qiang Gong, et al.
Blood|October 22, 2005
Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletionsLisa M Rimsza, Robin A Roberts, Elias Campo, et al.
Blood|August 23, 2021
Insertion of atypical glycans into the tumor antigen-binding site identifies DLBCLs with distinct origin and behaviorGiorgia Chiodin, Joel D Allen, Dean J Bryant, et al.
Haematologica|November 3, 2009
SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtypeAna Mozos, Cristina Royo, Elena Hartmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2011
BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximabJaveed Iqbal, Paul N Meyer, Lynette M Smith, et al.
Pageof 29